Effect of sirolimus on disease progression in patients with autosomal dominant polycystic kidney disease and CKD stages 3b-4

Clinical Journal of the American Society of Nephrology

Volumn 11, Issue 5, 2016, Pages 785-794

  Ruggenenti, Piero ^a,b   Gentile, Giorgio ^a,b   Perico, Norberto ^a   Perna, Annalisa ^a   Barcella, Luca ^b   Trillini, Matias ^a   Cortinovis, Monica ^a   Ferrer Siles, Claudia Patricia ^a   Reyes Loaeza, Jorge Arturo ^a   Aparicio, Maria Carolina ^a   Fasolini, Giorgio ^b   Gaspari, Flavio ^a   Martinetti, Davide ^a   Carrara, Fabiola ^a   Rubis, Nadia ^a   Prandini, Silvia ^a   Caroli, Anna ^a   Sharma, Kanishka ^a   Antiga, Luca ^a   Remuzzi, Andrea ^a   Remuzzi, Giuseppe ^a,b,c   more..

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Adult; Adverse effects; Humans; Kidney failure, chronic; Polycystic kidney, autosomal dominant; Prospective studies; Proteinuria; Randomized controlled trials; Renal insufficiency; Sirolimus

Indexed keywords

ALANINE AMINOTRANSFERASE; CALCIUM; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT;

ACNE; ALBUMINURIA; ANGIONEUROTIC EDEMA; ANUS FISSURE; APHTHOUS STOMATITIS; ARTICLE; BODY WEIGHT; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DISEASE COURSE; DIVERTICULITIS; DYSMENORRHEA; DYSPEPSIA; END STAGE RENAL DISEASE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEMATOCRIT; HEMATURIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY POLYCYSTIC DISEASE; PERIPHERAL EDEMA; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERNER MORRISON SYNDROME; ADULT; CHEMICALLY INDUCED; COMPLICATION; DISEASE EXACERBATION; EARLY TERMINATION OF CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; ALBUMINURIA; DISEASE PROGRESSION; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROSPECTIVE STUDIES; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; SIROLIMUS;

EID: 85012178862     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.09900915     Document Type: Article

References (35)

1. Gabow PA: Autosomal dominant polycystic kidney disease. N Engl J Med 329: 332–342, 1993
2. Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, Grantham JJ: Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 63: 1983–1994, 2003
3. Bhunia AK, Piontek K, Boletta A, Liu L, Qian F, Xu PN, Germino FJ, Germino GG: PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell 109: 157–168, 2002
4. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 103: 5466–5471, 2006
5. Fingar DC, Blenis J: Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151–3171, 2004
6. Wu M, Arcaro A, Varga Z, Vogetseder A, Le Hir M, Wüthrich RP, Serra AL: Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease. Am J Physiol Renal Physiol 297: F1597–F1605, 2009
7. Tao Y, Kim J, Schrier RW, Edelstein CL: Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 16: 46–51, 2005
8. Zafar I, Belibi FA, He Z, Edelstein CL: Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). Nephrol Dial Transplant 24: 2349–2353, 2009
9. Perico N, Antiga L, Caroli A, Ruggenenti P, Fasolini G, Cafaro M, Ondei P, Rubis N, Diadei O, Gherardi G, Prandini S, Panozo A, Bravo RF, Carminati S, De Leon FR, Gaspari F, Cortinovis M, Motterlini N, Ene-Iordache B, Remuzzi A, Remuzzi G: Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol 21: 1031–1040, 2010
10. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wüthrich RP: Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363: 820–829, 2010
11. Walz G, Budde K, Mannaa M, Nürnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hörl WH, Obermüller N, Arns W, Pavenstädt H, Gaedeke J, Büchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU: Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363: 830–840, 2010
12. Gaspari F, Perico N, Matalone M, Signorini O, Azzollini N, Mister M, Remuzzi G: Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease. J Am Soc Nephrol 9: 310–313, 1998
13. Ruggenenti P, Gaspari F, Cannata A, Carrara F, Cella C, Ferrari S, Stucchi N, Prandini S, Ene-Iordache B, Diadei O, Perico N, Ondei P, Pisani A, Buongiorno E, Messa P, Dugo M, Remuzzi G; GFR-ADPKD Study Group: Measuring and estimating GFR and treatment effect in ADPKD patients: Results and implications of a longitudinal cohort study. PLoS One 7: e32533, 2012
14. Cattaneo D, Perico N, Gaspari F: Assessment of sirolimus concentrations in whole blood by high-performance liquid chro-matography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 774: 187–194, 2002
15. Ibanez L, Schroeder W, Ng L, Cates J: The ITK SoftwareGuide, 2nd Ed., Albany, NY, Kitware Inc., 2005
16. Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, Li J, King BF, Martin D, Wetzel LH, Lockhart ME, Harris PC, Moxey-Mims M, Flessner M, Bennett WM, Grantham JJ: Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 7: 479–486, 2012
17. Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G: Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 35: 1155–1165, 2000
18. Gupta SK: Intention-to-treat concept: A review. Perspect Clin Res 2: 109–112, 2011
19. Carpenter JR, Kenward M: Missing Data in Randomised Controlled Trials—A Practical Guide. Birmingham: National Institute for Health Research, Publication RM03/JH17/MK, 2008. Available at: http://www.missingdata.org.uk. Accessed February 8, 2016
20. Burdese M, Rossetti M, Guarena C, Consiglio V, Mezza E, Soragna G, Gai M, Segoloni GP, Piccoli GB: Sirolimus and ACE-inhibitors: A note of caution. Transplantation 79: 251–252, 2005
21. Duerr M, Glander P, Diekmann F, Dragun D, Neumayer HH, Budde K: Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol 5: 703–708, 2010
22. Ward PE, Chow A, Drapeau G: Metabolism of bradykinin agonists and antagonists by plasma aminopeptidase P. Biochem Pharmacol 42: 721–727, 1991
23. Ahmad S, Wang L, Ward PE: Dipeptidyl(amino)peptidase IV and aminopeptidase M metabolize circulating substance P in vivo. J Pharmacol Exp Ther 260: 1257–1261, 1992
24. Byrd JB, Woodard-Grice A, Stone E, Lucisano A, Schaefer H, Yu C, Eyler AE, Salloum NE, Brown NJ: Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use. Allergy 65: 1381–1387, 2010
25. Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW: Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol 4: 820–829, 2009
26. Jafar TH, Stark PC, Schmid CH, Strandgaard S, Kamper AL, Maschio G, Becker G, Perrone RD, Levey AS; ACE Inhibition in Progressive Renal Disease (AIPRD) Study Group: The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int 67: 265–271, 2005
27. Kuypers DR: Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 28: 153–181, 2005
28. Rangan GK: Sirolimus-associated proteinuria and renal dysfunction. Drug Saf 29: 1153–1161, 2006
29. Saurina A, Campistol JM, Piera C, Diekmann F, Campos B, Campos N, de las Cuevas X, Oppenheimer F: Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: Changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant 21: 488–493, 2006
30. Torras J, Herrero-Fresneda I, Gulias O, Flaquer M, Vidal A, Cruzado JM, Lloberas N, Franquesa M, Grinyó JM: Rapamycin has dual opposing effects on proteinuric experimental nephropathies: Is it a matter of podocyte damage? Nephrol Dial Transplant 24: 3632–3640, 2009
31. Chapman AB, Johnson AM, Gabow PA, Schrier RW: Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5: 1349–1354, 1994
32. Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, Jones RH: Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 41: 1311–1319, 1992
33. Braun WE, Schold JD, Stephany BR, Spirko RA, Herts BR: Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: An open-label randomized controlled pilot study. Clin J Am Soc Nephrol 9: 881–888, 2014
34. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367: 2407–2418, 2012
35. Caroli A, Perico N, Perna A, Antiga L, Brambilla P, Pisani A, Visciano B, Imbriaco M, Messa P, Cerutti R, Dugo M, Cancian L, Buongiorno E, De Pascalis A, Gaspari F, Carrara F, Rubis N, Prandini S, Remuzzi A, Remuzzi G, Ruggenenti P; ALADIN study group: Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): A randomised, placebo-controlled, multicentre trial. Lancet 382: 1485–1495, 2013